Conference Coverage: EHA 2022 – Focus on Lymphoma
Lymphoma-specific discussions on the latest research updates, therapeutic advances, and their application in clinical decision-making
FACULTY CHAIR
Brad S. Kahl, MD
Washington University School of Medicine, St Louis, MO, USA
Faculty Members
Matthew Lunning, DO, FACP
University of Nebraska Medical Center, Omaha, NE, USA
Paolo Caimi, MD
Case Comprehensive Cancer Center, Cleveland, OH, USA
Stefan Barta, MD, MS, MRCPCUK
Penn Medicine, Philadelphia, PA, USA
John Gribben, MD, DSc, FRCP, FRCPath
Cancer Research UK Barts Centre, London, United Kingdom
Pier Luigi Zinzani, MD, PhD
University of Bologna Institute of Hematology and Medical Oncology, Bologna, Italy
Olivier Tournilhac, MD, PhD
Clermont Auvergne University, Clermont-Ferrand, France
Georg Hess, MD
Johannes Gutenberg University, Mainz, Germany
REPORT SNAPSHOT
- Advances in DLBCL/Aggressive B-Cell Lymphoma
- Advances in CAR T
- Advances in FL
- Advances in MCL and MZL
- Evolving Use of BTK Inhibitors in CLL
- Role of Fixed-Duration and MRD-Guided Strategies in CLL
